EG 427

At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs are in Paris, France, where...

Gene therapy,peripheral nervous system disorders,neurogenic bladder,hsv-1 vector platform,urinary bladder dysfunction,herpes type 1 gene therapy platform,and treatment of nervous system disorders

Eg 427 operates in the Biotechnology research industry.

Eg 427's revenue is 11m - 100m

Eg 427 has 11 - 50 employees.